The rising prevalence of cancer, rapid growth in geriatric population, and increasing number of emergency surgeries are some of the major factors driving the growth of the US general anesthesia drugs.
The US general anesthesia drugs market size is projected to reach USD 2.4 billion by 2025 from USD 2.0 billion in 2020, at a CAGR of 3.4% during the forecast period.
Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=713
Market Segmentation: -
Intravenous anesthesia drugs accounted for the largest share in the US general anesthesia drugs market in 2019.
Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs. The inhalational anesthesia drugs is further categorized into sevoflurane, desflurane, isoflurane and nitrous oxide. Similarly, intravenous anesthesia drugs are further categorized into propofol, benzodiazepines, ketamine, methohexital sodium and others intravenous general anesthesia drugs. The intravenous segment accounted for the largest share of the market. General intravenous anesthesia drugs are less expensive and do not require expensive machines for administration which contributes to the high market share of the segment.
Hospitals accounted for the largest share in the US general anesthesia drugs market in 2019
Based on end user, the US general anesthesia drugs market has been segmented into hospitals and ambulatory surgery centers. The hospitals segment accounted for the largest share of the US general anesthesia drugs market in 2019. The massive patient footfall in hospitals and the increasing number of surgeries performed in these facilities are the factors responsible for the largest share of the segment.
Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=713
Key Market Players: -
The US general anesthesia drugs market is dominated by a few established players such as Baxter International Inc. (US), Hikma Pharmaceuticals plc (UK), Pfizer Inc. (US), Piramal Enterprises Limited (India), AbbVie (US), Fresenius SE & Co. KGaA (Germany), Par Pharmaceutical (US), Teva Pharmaceuticals (Israel), Viatris/Mylan (US), Novartis AG (US), Abbott Laboratories (US), AstraZeneca plc (US), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (UK), Gilead Sciences, Inc. (US), Bayer AG (Germany), Merck & Co., Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (US), Akorn (US), and Apotex (Canada) among others.
The rising prevalence of cancer, rapid growth in geriatric population, and increasing number of emergency surgeries are some of the major factors driving the growth of the US general anesthesia drugs.The US general anesthesia drugs market size is projected to reach USD 2.4 billion by 2025 from USD 2.0 billion in 2020, at a CAGR of 3.4% during the forecast period.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=713Market Segmentation: -Intravenous anesthesia drugs accounted for the largest share in the US general anesthesia drugs market in 2019.Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.
The inhalational anesthesia drugs is further categorized into sevoflurane, desflurane, isoflurane and nitrous oxide.
Similarly, intravenous anesthesia drugs are further categorized into propofol, benzodiazepines, ketamine, methohexital sodium and others intravenous general anesthesia drugs.
The intravenous segment accounted for the largest share of the market.
General intravenous anesthesia drugs are less expensive and do not require expensive machines for administration which contributes to the high market share of the segment.Hospitals accounted for the largest share in the US general anesthesia drugs market in 2019Based on end user, the US general anesthesia drugs market has been segmented into hospitals and ambulatory surgery centers.
The hospitals segment accounted for the largest share of the US general anesthesia drugs market in 2019.
General anesthesia drugs are administered to a patient to bring state of reversible unconsciousness and unresponsiveness before and during surgery.
Sometimes based on the condition, both the routes are used simultaneously to anesthetize the patient.
General anesthesia drugs are intended to bring about analgesia or pain relief, amnesia, reversible unconsciousness, motionlessness, and inhibition of autonomic nervous system such as increased blood pressure, heart rate, and sweating, and to perform easier and safer surgery.
Read Report Overview – https://www.transparencymarketresearch.com/general-anesthsia-drugs-market.htmlCurrently, there is a lack of standardization for technique in general anesthesia management.
Further, the technological advancements in drug delivery devices, development of specific targeted drugs and patient monitoring devices for monitoring physiological parameters of patients during and after anesthesia, and minimized side effects of anesthetic drugs are drivers which are likely to boost the market growth during the forecast period.
However, lack of health care facilities in underdeveloped countries and in remote areas and few anesthetic doctors and certified anesthetic nurses per capita of population are anticipated to restrain the growth of the general anesthesia drugs market.
